Patents by Inventor Juan Carlos Almagro

Juan Carlos Almagro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding human oncostatin M antibodies
    Patent number: 9587018
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 7, 2017
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20160009798
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 14, 2016
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Human Anti-CD27 Antibodies, Methods and Uses
    Publication number: 20150299330
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: July 2, 2015
    Publication date: October 22, 2015
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human oncostatin M antibodies
    Patent number: 9163083
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 20, 2015
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Human anti-CD27 antibodies, methods and uses
    Patent number: 9102737
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 11, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human tissue factor antibody and uses thereof
    Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8951525
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 10, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF
    Publication number: 20140234304
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Juan Carlos ALMAGRO, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Humanized IL-25 antibodies
    Patent number: 8785605
    Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: July 22, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
  • Human tissue factor antibody and uses thereof
    Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20140099315
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Methods of affinity maturing antibodies
    Patent number: 8580714
    Abstract: The invention relates to methods of affinity maturing antibodies.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 12, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Johan Fransson, Gopalan Raghunathan
  • HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES
    Publication number: 20130243795
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 19, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • IL-17A antibodies
    Patent number: 8519107
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 27, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20130189250
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 25, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20120237528
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20120093833
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 19, 2012
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas
  • Humanized IL-25 Antibodies
    Publication number: 20110318353
    Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).
    Type: Application
    Filed: March 30, 2011
    Publication date: December 29, 2011
    Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
  • IL-17A Antagonists
    Publication number: 20110236390
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 29, 2011
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
  • Methods of Affinity Maturing Antibodies
    Publication number: 20110092372
    Abstract: The invention relates to methods of affinity maturing antibodies.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 21, 2011
    Inventors: JUAN CARLOS ALMAGRO, JOHAN FRANSSON, GOPALAN RAGHUNATHAN